KEY FINDINGS
The Asia-Pacific DNA sequencing market is predicted to record a CAGR of 17.58% during the forecast period, 2021-2028. The rising use of DNA sequencing and its surging demand in the healthcare industry are among the primary growth drivers.
MARKET INSIGHTS
Thailand, Japan, China, Vietnam, Australia & New Zealand, India, Indonesia, South Korea, and Rest of Asia-Pacific, are assessed for the Asia-Pacific DNA sequencing market growth evaluation. In Japan, the increasing R&D and technological advancements in DNA sequencing drive market growth. The research and development expenses increased to 3.26% in 2018 from 3.15% of GDP in 2016, as per the UNESCO Institute for Statistics data. Also, there is increasing competition for DNA sequencing among leading market players in the country.
In Thailand, government initiatives promote market growth. For instance, the launch of the Genomics Thailand Initiative in 2019 to sequence genomes of almost 50,000 population, and infrastructure development to harness genomic information. The country established a Thailand Genomics Sequencing Center in 2020 in its high-tech Eastern Economic Corridor (EEC) to better its role as a global medical hub. Further, the Ministry of Higher Education, Science, Research, and Innovation, the Ministry of Higher Education, the Health Systems Research Institute, the Ministry of Public Health, and the Eastern Economic Corridor Office, collaborate to develop genomics medicine. Such considerable developments in genomic researches propel market growth in Thailand.
COMPETITIVE INSIGHTS
Some of the market’s prominent companies are BGI Genomics, Agilent Technologies Inc, F. Hoffmann-La Roche, Illumina Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING NEED FOR DNA SEQUENCING IN ANIMALS & PLANT REPRODUCTION
3.1.2. TECHNOLOGICAL DEVELOPMENTS
3.1.3. GROWING RESEARCH AND DEVELOPMENT IN DNA SEQUENCING
3.1.4. PREVALENCE OF CANCER CASES
3.1.5. USAGE OF LIQUID BIOPSY APPLICATIONS
3.1.6. IMPLEMENTATION OF GENOME MAPPING PROGRAMS
3.2. KEY RESTRAINTS
3.2.1. ACCURACY AND STANDARDIZATION CONCERNS IN DIAGNOSTIC TESTING
3.2.2. LACK OF SKILLED PROFESSIONALS IN EMERGING ECONOMIES
3.2.3. LIMITATIONS IN BIOINFORMATICS
3.2.4. SOCIAL AND ETHICAL ISSUES
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DNA SEQUENCING MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
5. MARKET BY TECHNOLOGY
5.1. SEQUENCING BY SYNTHESIS
5.2. ION SEMICONDUCTOR SEQUENCING
5.3. CHAIN TERMINATION SEQUENCING
5.4. PYROSEQUENCING
5.5. SEQUENCING BY LIGATION (SBL)
5.6. SINGLE-MOLECULE REAL-TIME SEQUENCING (SMRT)
5.7. NANOPORE SEQUENCING
5.8. OTHER TECHNOLOGIES
6. MARKET BY APPLICATION
6.1. BIOMARKER DISCOVERY
6.2. DIAGNOSTICS
6.3. REPRODUCTIVE HEALTH
6.4. PERSONALIZED MEDICINE
6.5. DRUG DISCOVERY
6.6. AGRICULTURE & ANIMAL RESEARCH
6.7. FORENSICS
6.8. OTHER APPLICATIONS
7. MARKET BY PRODUCT
7.1. INSTRUMENTS & CONSUMABLES
7.1.1. INSTRUMENTS & CONSUMABLES TYPE
7.1.1.1. CONSUMABLES
7.1.1.2. INSTRUMENTS
7.1.2. INSTRUMENTS & CONSUMABLES PLATFORM
7.1.2.1. NGS (NEXT GENERATION SEQUENCING)
7.1.2.1.1. RNA SEQUENCING
7.1.2.1.2. TARGETED RESEQUENCING
7.1.2.1.3. WHOLE-EXOME SEQUENCING
7.1.2.1.4. WHOLE-GENOME SEQUENCING
7.1.2.1.5. CHIP SEQUENCING
7.1.2.1.6. DE NOVO SEQUENCING
7.1.2.1.7. METHYL SEQUENCING
7.1.2.2. SANGER
7.2. SEQUENCING SERVICES
7.3. BIOINFORMATICS
8. MARKET BY END-USER
8.1. RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
8.2. PHARMACEUTICAL
8.3. BIOTECHNOLOGY COMPANIES
8.4. HOSPITALS & CLINICS
8.5. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. CHINA
9.1.5.2. JAPAN
9.1.5.3. INDIA
9.1.5.4. AUSTRALIA & NEW ZEALAND
9.1.5.5. SOUTH KOREA
9.1.5.6. THAILAND
9.1.5.7. INDONESIA
9.1.5.8. VIETNAM
9.1.5.9. REST OF ASIA-PACIFIC
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ADAPTIVE BIOTECHNOLOGIES INC
10.2.2. AGILENT TECHNOLOGIES INC
10.2.3. ASURAGEN INC
10.2.4. BGI GENOMICS
10.2.5. BIO-RAD LABORATORIES INC
10.2.6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
10.2.7. EUROFINS SCIENTIFIC
10.2.8. F. HOFFMANN-LA ROCHE
10.2.9. ILLUMINA INC
10.2.10. MERCK KGAA
10.2.11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
10.2.12. PERKINELMER INC
10.2.13. SIEMENS HEALTHINEERS AG
10.2.14. SPIRAL GENETICS INC
10.2.15. THERMO FISHER SCIENTIFIC INC
10.2.16. UBIQUITY GENOMICS INC
1. ADAPTIVE BIOTECHNOLOGIES INC
2. AGILENT TECHNOLOGIES INC
3. ASURAGEN INC
4. BGI GENOMICS
5. BIO-RAD LABORATORIES INC
6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
7. EUROFINS SCIENTIFIC
8. F. HOFFMANN-LA ROCHE
9. ILLUMINA INC
10. MERCK KGAA
11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
12. PERKINELMER INC
13. SIEMENS HEALTHINEERS AG
14. SPIRAL GENETICS INC
15. THERMO FISHER SCIENTIFIC INC
16. UBIQUITY GENOMICS INC
